Transcatheter repair wins for severe tricuspid regurgitation

MUNICH — A strategy of transcatheter tricuspid valve repair on top of optimal medical therapy was superior to medical therapy alone for patients with symptomatic severe tricuspid regurgitation and heart failure, according to new data.
In addition to improvements in quality of life previously seen in tricuspid valve repair trials, the interventional was associated with meaningful reductions in all-cause death and HF hospitalization — benefits that emerged early and were sustained up to 3 years, researchers reported at the European Society of Cardiology Congress.
“For most of

Digital strategy boosts SGLT2 inhibitor use in patients with HF

MUNICH — A digital strategy involving an emailed letter inviting patients with heart failure to be evaluated by a specialist for SGLT2 inhibitor therapy dramatically increased SGLT2 inhibitor prescriptions, researchers reported.
For the EMAIL-HF registry-based randomized trial, presented at the European Society of Cardiology Congress, researchers identified all patients with HF in the Capital Region of Denmark and the municipality of Roskilde who were not receiving an SGLT2 inhibitor and randomly assigned them to the digital strategy or the usual care. Patients in the digital strategy

More than half of healthy adults have silent atherosclerosis

MUNICH — More than half of healthy adults in Denmark and Spain had silent atherosclerosis detected across three vascular territories via imaging, including nearly 9% of men and 7% of women aged 18 to 29 years, according to new data.
“More than half of the study population of 16,808 healthy individuals aged 18 to 70 years had atherosclerosis,” Henning Bundgaard, MD, DMSc, from the department of cardiology, the Heart Center, Rigshospitalet, Copenhagen University Hospital, Denmark, said during a press conference at the European Society of Cardiology Congress. “This is a disease that may lead to

‘Trade-off’ of extended DAPT vs. monotherapy after DES implant

MUNICH — In patients at high ischemic risk implanted with a drug-eluting stent who had 12 months of dual antiplatelet therapy, switching to clopidogrel monotherapy increased ischemic events but reduced bleeding events, a speaker reported.
Byeong-Keuk Kim, MD, PhD, professor in the department of internal medicine at Yonsei University College of Medicine in Seoul, South Korea, said during a presentation at the European Society of Cardiology Congress that these data may caution against routine antiplatelet therapy deescalation in patients who may be at elevated ischemic risk.
“Current